Sandrock AlfredDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Apr 3, 2026Period of report Apr 2, 20260001104659-26-039691
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
SaleApr 2, 2026 | Common StockF1F2 | 11,511 | $3.87 | $44.55K | 472,549 | Direct |
Filing footnotes · 2
- F1Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.